Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › CRBU

Caribou Biosciences

CRBU 5 Biotech Distilled articles ↓ 26 filings & releases ↓ Cash $26.1M (Sep 30, 2026) ↓ 5 verdicts ↓

Market cap $48.5M 108.0M shares (10-Q, Nov 2, 2026) × $0.449 close Nov 6, 2026

Most recent annual filing: 2026-03-05

Pipeline (0 active programs)

No active programs disclosed.

Technology platforms

chRDNA

CRISPR hybrid RNA-DNA (chRDNA) genome-editing technology using hybrid guides containing both RNA and DNA for editing genomic DNA; enables high-specificity multiplex genome editing for ex vivo allogeneic CAR-T cell therapies; focus areas include oncology and autoimmune diseases

Targets: CD19, BCMA

Discontinued (6)

Capital (as filed)

Cash
$26.1M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$68.7M Sep 30, 2026
Operating cash flow
−$22.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$114M cash per the update of Oct 6, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Caribou Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-04-17 Watch Caribou Biosciences (CRBU) - Scientific Deep Dive for Vispa-cel and CB-011 Exceptional Phase 1 data and rational biology, but the looming cash cliff and inability to fund the Phase 3 trial make this a wait-for-dilution-to-clear situation.
  2. 2026-05-08 Speculative buy speculative UPDATE: Caribou Biosciences (CRBU) - The FDA Said Yes, The Bank Account Said "About That..." FDA alignment on a clean ANTLER-3 pivotal design retires the regulatory bear case, and at ~$186M market cap the enterprise value of ~$67M for two RMAT-designated programs is compelling as a lottery-ticket-sized position despite the unresolved financing overhang.
  3. 2026-06-11 Speculative buy speculative UPDATE: Caribou Biosciences (CRBU) - The Durability Box Gets Checked 17.1-month median PFS for vispa-cel and 50% of CB-011 patients still in deep remission at 15 months materially de-risks the allogeneic-curse bear case, while the financing overhang remains the binding constraint at ~$70-75M enterprise value.
  4. 2026-08-14 Speculative buy speculative UPDATE: Caribou Biosciences (CRBU) - The ATM Stopped Being a Token The speculative buy thesis is maintained as the science remains strong and EV is still ~$75-80M, but material ATM dilution (~12.7% share growth in seven months) with no partnership in sight warrants patience over accumulation ahead of the H2 CB-011 dose-expansion readout.
  5. 2026-10-07 Avoid UPDATE: Caribou Biosciences (CRBU) - The Cash Cliff Won Both programs discontinued, the H2 catalyst cancelled, and the stock appears to trade above estimated net cash after wind-down costs, leaving only a speculative liquidation/asset-sale bet with no defined timeline.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (26)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)